Idiosyncratic toxicity: A convergence of risk factors

Annual Review of Medicine

Volumn 58, Issue , 2007, Pages 17-34

  Ulrich, Roger G ^a  

^a ROSETTA INPHARMATICS   (United States)

Author keywords

Adverse drug reaction; Drug induced liver injury; Idiosyncratic drug reaction

Indexed keywords

BROMFENAC; CERIVASTATIN; DICLOFENAC; GEMFIBROZIL; IBUPROFEN; PARACETAMOL; PEMOLINE; RANITIDINE; SULFAMETHOXAZOLE; TROVAFLOXACIN; VALPROIC ACID; CYTOCHROME P450; DRUG;

CELL FUNCTION; COVALENT BOND; DIET; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG WITHDRAWAL; GENDER; GENETIC PREDISPOSITION; GENETICS; HUMAN; INNATE IMMUNITY; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MARKET; NONHUMAN; NUTRITIONAL STATUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STEVENS JOHNSON SYNDROME; AGE; DRUG EFFECT; DRUG TOXICITY; HEALTH STATUS; LIVER; METABOLISM; PHYSIOLOGY;

AGE FACTORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG TOXICITY; HEALTH STATUS; HUMANS; IMMUNITY, NATURAL; LIVER; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 34047172727     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.58.072905.160823     Document Type: Review

References (100)

1. Park BK, Pirmohamed M, Kitteringham NR. 1992. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34:377-95
2. Murphy EJ, Davern TJ, Shakil AO, et al. 2000. Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig. Dis. Sci. 45:549-53
3. Pasternak RC, Smith SCJ, Bairey-Merz CN, et al., for the American College of Cardiology, American Heart Association, and National Heart Lung and Blood Institute. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106:1024-28
4. Reye RDK, Morgan G, Basal J. 1963. Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood. Lancet 2:749-52
5. Belay ED, Bresee JS, Holman RC, et al. 1999. Reye's syndrome in the United States from 1981 through 1997. N. Engl. J. Med. 340:1377-82
6. Deschamps D, Fisch C, Fromenty B, et al. 1991. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J. Pharmacol. Exp. Ther. 259:894-904
7. Chang PF, Huang SF, Hwu WL, et al. 2000. Metabolic disorders mimicking Reye's syndrome. J. Formos. Med. Assoc. 99:295-99
8. Sim KG, Hammond J, Wilcken B. 2002. Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin. Chim. Acta 323:37-58
9. Waller P, Suvarna R. 2004. Is aspirin a cause of Reye's syndrome? Drug Saf. 24:71-73
10. Zhou S, Yung Chan S, Cher Goh B, et al. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44:279-304
11. Nelson SD. 2001. Structure toxicity relationships - how useful are they in predicting toxicities of new drugs? Adv. Exp. Med. Biol. 500:33-43
12. Goldkind L, Laine L. 2006. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol. Drug Saf. 15:213-20
13. Williams DP, Park BK. 2003. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov. Today 8(22):1044-50
14. Boelsterli UA. 2003. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192:307-22
15. King C, Tang W, Ngui J, et al. 2001. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol. Sci. 61:49-53
16. Sanderson JP, Naisbitt DJ, Park BK. 2006. Role of bioactivation in drug-induced hypersensitivity reactions. Am. Assoc. Pharm. Sci. J. 8:E55-64
17. Naisbitt DJ, Farrell J, Gordon SF, et al. 2002. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 62:628-37
18. Reilly TP, Lash LH, Doll MA, et al. 2000. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol. 114:1164-73
19. Cribb AE, Miller M, Tesoro A, Spielberg SP. 1990. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol. Pharmacol. 38:744-51
20. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 2004. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17:3-16
21. Ulrich RG, Bacon JA, Brass EP, et al. 2001. Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem. Biol. Interact. 134:251-70
22. Eyer F, Felgenhauer N, Gempel K, et al. 2005. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J. Clin. Psychopharmacol. 25:376-80
23. Moreno FA, Macey H, Schreiber B. 2005. Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study. J. Clin. Psychiatry 66:555-58
24. Granneman GR, Wang SI, Kesterson JW, Machinist JM. 1984. The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 4:1153-58
25. Kurt TL, Anderson R, Petty C, et al. 1986. Dinitrophenol in weight loss: the poison center and public health safety. Vet. Hum. Toxicol. 28:574-75
26. Honkoop P, Scholte HR, de Man RA, Schalm SW. 1997. Mitochondrial injury. Lessons from the fialuridine trial. Drug Saf. 17:1-7
27. Miro O, Lopez S, Cardellach F, Casademont J. 2005. Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir. Ther. 10(Suppl. 2):M73-81
28. Soriano A, Miro O, Mensa J. 2005. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 353:2305-6
29. Pessayre D, Mansouri A, Haouzi D, Fromenty B. 1999. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 15:367-73
30. Giardina WJ, Dart MJ, Harris RR, et al. 2005. Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity. Epilepsia 46:1349-61
31. Zanelli U, Puccini P, Acerbi D, et al. 1996. Selective depletion of mitochondrial glutathione content by pivalic acid and valproic acid in rat liver: possibility of a common mechanism. Adv. Exp. Med. Biol. 387:107-11
32. Battaglia V, Salvi M, Toninello A. 2005. Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria. J. Biol. Chem. 280:33864-72
33. Amacher DE. 2005. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem. 12:1829-39
34. Jolly RA, Ciurlionis R, Morfitt D, et al. 2004. Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression. Toxicol. Pathol. 32(Suppl. 2):19-25
35. Bjornsson E, Olsson R. 2006. Suspected drug-induced liver fatalities reported to the WHO database. Dig. Liver Dis. 38:33-38
36. Lee WM. 2004. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 40:6-9
37. Kaplowitz N. 2006. Liver biology and pathobiology. Hepatology 43:S235-38
38. Riley TR, Smith JP. 1998. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am. J. Gastroenterol. 93:1563-65
39. Nunez M. 2006. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J. Hepatol. 44:S132-39
40. Sterling RK, Sulkowski MS. 2004. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Semin. Liver Dis. 24 (Suppl. 2):61-68
41. Salazar-Mather TP, Hokeness KL. 2006. Cytokine and chemokine networks: pathways to antiviral defense. Curr. Top. Microbiol. Immunol. 303:29-46
42. Diehl AM, Li ZP, Lin HZ, Yang SQ. 2005. Cytokines and the pathogenesis of nonalcoholic steatohepatitis. Gut 54:303-6
43. Farrell GC, Larter CZ. 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:S99-S112
44. Grieco A, Forgione A, Miele L, et al. 2005. Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. 9:261-63
45. Ribeiro PS, Cortez-Pinto H, Sola S, et al. 2004. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 99:1708-17
46. Romics LJ, Kodys K, Dolganiuc A, et al. 2004. Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver. Hepatology. 40:376-85
47. Dela Pena A, Leclercq I, Field J, et al. 2005. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology. 129:1663-74
48. Begriche K, Igoudjil A, Pessayre D, Fromenty B. 2006. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6:1-38
49. Wang T, Zhang X, Li JJ. 2002. The role of NF-kappaB in the regulation of cell stress responses. Int. Immunopharmacol. 2:1509-20
50. Yang S, Lin H, Diehl AM. 2001. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G382-92
51. DeAngelis RA, Markiewski MM, Taub R, Lambris JD. 2005. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology 42:1148-57
52. Riley TR, Kahn A. 2006. Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease. Dig. Dis. Sci. 51:41-44
53. Chiappini F, Barrier A, Saffroy R, et al. 2006. Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab. Invest. 86:154-65
54. Honda M, Kawai H, Shirota Y, et al. 2005. cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J. Autoimmun. 25:133-40
55. Clouatre Y, Leblanc M, Ouimet D, Pichette V. 1999. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol. Dial. Transplant. 14:1047-48
56. Kursat S, Alici T, Colak HB. 2005. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism. Clin. Nephrol. 64:391-93
57. Ganey PE, Luyendyk JP, Maddox JF, Roth RA. 2004. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem. Biol. Interact. 150:35-51
58. Luyendyk JP, Maddox JF, Cosma GN, et al. 2003. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307:9-16
59. Waring JF, Liguori MJ, Luyendyk JP, et al. 2006. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther. 316:1080-87
60. Chang JT, Staffa JA, Parks M, Green L. 2004. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol. Drug Saf. 13:417-26
61. Singh SS. 2006. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr. Drug Metab. 7:165-82
62. Mahady GB. 2001. Global harmonization of herbal health claims. J. Nutr. 131:1120S-23S
63. Durazo FA, Lassman C, Han SH, et al. 2004. Fulminant liver failure due to usnic acid for weight loss. Am. J. Gastroenterol. 99:950-52
64. Han D, Matsumaru K, Rettori D, Kaplowitz N. 2004. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem. Pharmacol. 67:439-51
65. Neff GW, Reddy KR, Durazo FA, et al. 2004. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J. Hepatol. 41:1062-64
66. Stedman C. 2002. Herbal hepatotoxicity. Semin. Liver Dis. 22:195-206
67. Krueger KJ, McClain CJ, McClave SA, Dryden GW. 2004. Nutritional supplements and alternative medicine. Curr. Opin. Gastroenterol. 20:130-38
68. Smith DJ, Olive KE. 2003. Chinese red rice-induced myopathy. South. Med. J. 96:1265-67
69. Eisenbrand G. 2006. Toxicological evaluation of red mold rice. Mol. Nutr. Food Res. 50:322-27
70. Zhou S, Koh HL, Gao Y, et al. 2004. Herbal bioactivation: the good, the bad and the ugly. Life Sci. 74:935-68
71. Hu Z, Yang X, Ho PC, et al. 2005. Herb-drug interactions: a literature review. Drugs 65:1239-82
72. Pal D, Mitra AK. 2006. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 78:2131-45
73. Kilbourne EM, Philen RM, Kamb ML, Falk H. 1996. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. J. Rheumatol. 46:81-88
74. Hare JT, Elliott DP. 2003. Grapefruit juice and potential drug interactions. Constat. Pharm. 18:466-72
75. Marcason W. 2005. What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors? J. Am. Diet. Assoc. 105:163
76. Murray M. 2006. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr. Drug Metab. 7:67-81
77. Sherratt HAS. 1986. Hypoglycin, the famous toxin of the unripe Jamaican ackee fruit. Trends Pharmacol. Sci. 7:186-91
78. Dart RC, Erdman AR, Olson KR, et al. 2006. American Association of Poison Control Centers. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin. Toxicol. (Phila.) 44:1-18
79. Pineiro-Carrero VM, Pineiro EO. 2004. Liver. Pediatrics 113:1097-106
80. Rumack BH. 1984. Acetaminophen overdose in young children. Treatment and effects of alcohol and other additional ingestants in 417 cases. Am. J. Dis. Child. 138:428-33
81. Kondo T, Kaneko S, Otani K, et al. 1992. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 33:172-77
82. Marotta PJ, Roberts EA. 1998. Pemoline hepatotoxicity in children. J. Pediatr. 132:894-97
83. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. 2002. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 110:e53
84. Caamano F, Pedone C, Zuccala G, Carbonin P. 2005. Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. Arch. Gerontol. Geriatr. 40:45-52
85. Hajjar ER, Hanlon JT, Artz MB, et al. 2003. Adverse drug reaction risk factors in older outpatients. Am. J. Geriatr. Pharmacother. 1:82-89
86. Stephen LJ. 2003. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 20:141-52
87. Bowman L, Carlstedt BC, Hancock EF, Black CD. 1996. Adverse drug reaction (ADR) occurrence and evaluation in elderly inpatients. Pharmacoepidemiol. Drug Saf. 5:9-18
88. Drici MD, Clement N. 2001. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf. 24:575-85
89. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A. 2002. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam. Clin. Pharmacol. 16:343-46
90. Thompson PD, Zmuda JM, Domalik LJ, et al. 1997. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 46:1206-10
91. Unnikrishnan D, Satish B. 2005. Exertion-induced rhabdomyolysis in a patient on statin therapy. Nephrol. Dial. Transplant. 20:244
92. Seachrist JL, Loi CM, Evans MG, et al. 2005. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol. Sci. 88:551-61
93. Eichelbaum M, Ingelman-Sundberg M, Evans WE. 2006. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57:119-37
94. Frank JE. 2005. Diagnosis and management of G6PD deficiency. Am. Fam. Physician. 72:1277-82
95. Finsterer J. 2004. Mitochondriopathies. Eur. J. Neurol. 11:163-86
96. Trenell MI, Sue CM, Kemp GJ, et al. 2006. Aerobic exercise and muscle metabolism in patients with mitochondrial myopathy. Muscle Nerve 33:524-31
97. Njolstad PR, Skjeldal OH, Agsteribbe E, et al. 1997. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity. Pediatr. Neurol. 16:160-62
98. Vladutiu GD, Simmons Z, Isackson PJ, et al. 2006. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34:153-62
99. Fischel-Ghodsian N. 1999. Genetic factors in aminoglycoside toxicity. Ann. NY Acad. Sci. 884:99-109
100. Clayton TA, Lindon JC, Cloarec O, et al. 2006. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073-77